Oxfendazole Development Group

Analysis

Oxfendazole Development Group is a registered charity in United States, based in Blue Bell, PA. It received its IRS tax-exemption ruling in July 2016, 10 years ago. Its declared purposes cover medical research, which this site groups under health and saving lives. The IRS classifies it as a publicly supported organisation (donations from the general public) under section 501(c)(3), and contributions to it are listed as tax-deductible.

In the financial year ending December 2023, Oxfendazole Development Group reported income of $59k and spending of $605k, spending 1033% of what it took in. Across the 2 years on record, from December 2022 to December 2023, income fell from $1.7m to $59k (-97%), an average of -97% a year. The sharpest change came in the year to December 2023, when income dropped by 97%. Over the whole period it spent 37% of the income it received.

Among 40,470 United States charities whose main cause is health and saving lives and that reported income, Oxfendazole Development Group sits at the 18th percentile: it is larger than about 18% of them. Against every charity in United States with reported income it ranks in the 23rd percentile, and in the 21st percentile within PA. Charities of a similar size with the same main cause include Autism Higher Education Foundation Inc ($58k), Pink Ride Inc ($59k) and Rockin on the River Fundraiser ($58k).

On its Form 990 for the period ending December 2023, revenue came from contributions and grants 14% of the total. At year end it held assets of $1.1m against liabilities of $0, net assets of $1.1m.